Sienna Biopharmaceuticals to Present at Cowen and Company Health Care Conference
05 Mars 2019 - 3:05PM
Sienna Biopharmaceuticals, Inc. (Nasdaq:SNNA), a clinical-stage
biopharmaceutical company, today announced that Frederick C.
Beddingfield III, M.D., Ph.D., President and Chief Executive
Officer of Sienna, is scheduled to present at the Cowen and Company
39th Annual Health Care Conference, Monday, Mar. 11, 2019, 11:20
a.m. EDT, in Boston.
The presentation will be webcast live and can be
accessed through the Investor Relations section of the Company’s
website at Investors.SiennaBio.com. An archived version of the
webcast will be available approximately two hours following the
live presentation for 90 days.
About Sienna Biopharmaceuticals
Sienna Biopharmaceuticals, Inc. is a
clinical-stage biopharmaceutical company focused on bringing
unconventional scientific innovations to patients whose lives
remain compromised by their disease. We draw upon our deep
knowledge and experience in drug development across multiple
therapeutic areas as we build a unique, diversified, multi-asset
portfolio of therapies in immunology and inflammation that target
select pathways in specific tissues, with an initial focus on one
of the most important ‘immune’ tissues, the skin. We are leading
the way with our novel technology platform, Topical by Design™,
applying a scientific design process to create potent targeted
pharmacologically active molecules that are directed toward a
specific target tissue and a select disease pathway, and with
minimal to no systemic exposure. At Sienna, we are going where it
still matters for patients.
For more information, visit the Company’s
website at www.SiennaBio.com.
Contact:
InvestorsSean
Andrewssandrews@siennabio.com818-629-2244
MediaCaroline Van
Hovecvanhove@siennabio.com818-575-6250
Sienna Biopharmaceuticals (NASDAQ:SNNA)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Sienna Biopharmaceuticals (NASDAQ:SNNA)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024
Real-Time news about Sienna Biopharmaceuticals Inc (NASDAQ): 0 recent articles
Plus d'articles sur